SBIR Phase II: Microchip Assay for Glycosylated Hemoglobin

这项小型企业创新研究（SBIR）二期项目旨在开发下一代糖尿病监测设备，该设备将允许使用创新的芯片实验室技术测量疾病调节和进展的多种标记。该项目将开发首个集成微芯片CE设备，用于测量糖尿病的重要制造商。这项技术将通过更有效地跟踪生物标志物以及在护理点使用，影响患者对疾病进展和治疗效果的监测。这消除了目前进行后续实验室测试所需的时间和成本。该技术从一种非传统的传感器机制接近生物标志物的化学性质，在检测和使用特定疾病的生物标志物方面显示出巨大的前景。

This Small Business Innovation Research (SBIR) Phase II project aims at developing the next generation of diabetic monitoring devices that will allow the measurement of multiple markers of disease regulation and progression using an innovative lab-on-a-chip technology. The project will develop the first integrated microchip CE device for measurement of an important maker of diabetes.This technology will impact patient monitoring for disease progression and therapeutic efficacy by following biomarker more efficiently as well as being used at the point of care. This eliminates the time and cost currently required to perform follow up laboratory tests. The technology approaches the chemistry of biomarkers from a non-traditional sensor mechanism and shows great promise for the detection and use of biomarkers for specific diseases.